To do so, pegylated full length IFNγ was conjugated to PDGFβR-recognizing peptide (PPB) [18] and by using this conjugate (i.e. PPB-PEG-IFNγ) we were able to demonstrate anti-fibrotic effects in the CCl4-induced liver fibrosis mouse model [19] and anti-tumorigenic effects by targeting stromal cells in the B16 melanoma tumor mouse model [20]. This evidence concerns the gene IFNG and Hepatic fibrosis.